CLEVELAND, March 20, 2018 -- Athersys, Inc. (NASDAQ:ATHX) announced today that Gil Van Bokkelen, Chairman and CEO, will present a corporate overview at the 17th Annual Needham Healthcare Conference at The Westin Grand Central Hotel in New York City. The presentation is scheduled for Wednesday, March 28, 2018 at 9:30 am ET.
Investors interested in arranging a meeting with the Company's management during this conference should contact the conference coordinator.
A live webcast of the presentation can be accessed by visiting ‘Events & Presentations’ in the Investors Section on the Company's website at www.athersys.com. An archived replay of the webcast will be available on the Company's website after the conference for a limited time.
About Athersys
Athersys is an international biotechnology company engaged in the development of therapeutic products designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, cardiovascular, and inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization. More information is available at www.athersys.com. Follow Athersys on Twitter at www.twitter.com/athersys.
ATHX-G
Contact:
William (B.J.) Lehmann
President and Chief Operating Officer
Tel: (216) 431-9900
[email protected]
Karen Hunady
Corporate Communications & Investor Relations
Tel: (216) 431-9900
[email protected]
David Schull
Russo Partners, LLC
Tel: (212) 845-4271 or (858) 717-2310
[email protected]


BHP Port Hedland Strike Set to Proceed as Wage Talks Continue
DeepSeek to Raise AI API Prices as Demand for New Models Surges
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations
Apple Restores Telegram to App Store After Content Policy Violation
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 



